Scholars Central

OtherPublished 12 Jul 2016

Telaprevir in the treatment of hepatitis C infection: evidence from the ADVANCE, ILLUMINATE and REALIZE studies

Authors: Joseph Ahn, Steven Flamm

Clinical Investigation

Volume 2 · Issue 2 · Pages 189–198

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Treatment of chronic hepatitis C (HCV) infection with PEGylated IFN-α and ribavirin is suboptimal, resulting in a growing number of treatment-failure patients who are left with limited treatment options. Telaprevir, a NS3/4A HCV protease inhibitor, was shown in Phase II studies to be efficacious and safe in treatment-naive and treatment-experienced genotype 1 patients. This article reviews the results of the recently reported Phase III studies: ADVANCE, ILLUMINATE and REALIZE, which reported sustained virological response as high as 75% in treatment-naive patients and 88% in prior relapse patients. Response-guided therapy using extended rapid virological response resulted in sustained virological response rates as high as 92% in treatment-naive patients with a short course of therapy. The addition of telaprevir to the therapeutic regimen for HCV genotype 1 represents a major advance in the management of chronic HCV.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Joseph Ahn”
  • BylineArticles whose byline prints “Steven Flamm”